A phase Ib/II study of AMG 655 or AMG 479 in combination with gemcitabine for metastatic pancreatic cancer

Community Oncology

Volumn 5, Issue 11 SUPPL. C, 2008, Pages 1-4

  Kindler, Hedy Lee ^a,b  

^a MC 2115 ^*  (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 479; AMG 655; GEMCITABINE; MONOCLONAL ANTIBODY; PANITUMUMAB; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 57149086097     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Friberg G, Kindler HL. Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep 2005;7:186-195.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
4. Kindler HL, Bylow K. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-176.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
6. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B 80303. J Clin Oncol 2007;25(18S):4508.
7. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885.
8. Derosier LC, Vickers SM, Zinn KR, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007;6(12 pt 1):3198-3207.
9. DeRosier LC, Huang ZQ, Sellers JC, Vickers SM. Treatment with gemcitabine and TRA-8 anti-death recpeptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J Gastrointest Surg 2006;10:1291-1300.
10. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-79.
11. Xu ZW, Kleeff J, Friess H, Büchler MW, Solioz M. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 2003;23:251-258.
12. Hylander BL, Pitoniak R, Penetrante RB, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22.
13. th Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, Calif. Abstract 3999.
14. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007;25(18S):3534.
15. Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 2003;301:46-55.
16. Bergmann U, Funatomi H, Yokoyama M, Begar HG, Korc M. Insulin like growth factor 1 overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-2011.
17. Beltran PJ, Mitchell P, Moody G, et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. J Clin Oncol 2008;26(15S):4617.
18. Min Y, Adachi Y, Yamamoto H, et al. Genetic blockade of the insulin-like growth factor-1 receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003;63:6432-6441.
19. Piao W, Wang Y, Adachi Y, et al. Insulin-like growth factor receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008;7:1483-1493.
20. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-1 receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003;163:1001-1011.
21. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007;25(18S):3002.
22. Sarantopoulos J, Mita A, Mulay M, et al. Safety and pharmacokinetics (PK) of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 2008;26(15S):3583.